Xontogeny

News

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development

Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies

Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders

Tellus Therapeutics Announces $35 Million Series A Financing

Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury

Surf Bio Announces $16 Million Series Seed Financing

VivoSense Announces Closing of $25M Series A Financing

Avenge Bio Announces Closing of $45 Million Series A Financing

Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II

Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP

Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies

Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)

Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics

Filter Results
  • View All
  • PXV
  • Xontogeny

September 27, 2023

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

July 25, 2023

A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development

June 20, 2023

Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

April 13, 2023

TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

March 1, 2023

CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies

January 15, 2023

Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders

December 13, 2022

Tellus Therapeutics Announces $35 Million Series A Financing

December 13, 2022

Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury

April 16, 2022

Surf Bio Announces $16 Million Series Seed Financing

March 30, 2022

VivoSense Announces Closing of $25M Series A Financing

January 5, 2022

Avenge Bio Announces Closing of $45 Million Series A Financing

November 15, 2021

Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II

May 12, 2021

Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP

May 12, 2021

Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies

May 12, 2021

Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

May 12, 2021

Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

May 12, 2021

Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury

May 12, 2021

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

May 12, 2021

Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)

October 22, 2020

Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics

July 21, 2020

Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies

June 24, 2020

AsclepiX Therapeutics Announces $35 Million Series A Financing

June 9, 2020

CereVasc Announces Closing of $43.9 Million Series A Financing

March 31, 2020

Zucara Therapeutics Announces $21 Million Series A Financing

December 10, 2019

Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups

December 10, 2019

Quellis Biosciences Inc. Announces $17 Million Series A Financing

August 12, 2019

Landos Biopharma Completes $60 Million Series B Financing

September 21, 2017

Landos Biopharma Raises $10 Million in Series A Financing

August 28, 2017

Xontogeny Appoints Industry Veteran Fred Callori as Senior Vice President of Corporate Development

May 18, 2017

Xontogeny, a New Accelerator Operating Company, Launches with a $25 Million Series A Financing to Advance Early Stage Life Sciences Technology through Clinical Proof-of-Concept